C4 Therapeutics, Inc.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science to develop a new generation of medicines. The company's mission is to transform the treatment of cancer and other diseases by selectively destroying disease-causing proteins. Headquartered in Watertown, Massachusetts, C4 Therapeutics leverages its proprietary TORPEDO® platform to efficiently design and optimize small-molecule medicines.

Utilizing its TORPEDO® platform, C4 Therapeutics focuses on harnessing the body's natural protein recycling system to degrade proteins that are difficult to target with traditional therapies. The company's pipeline primarily targets oncology, including hematologic malignancies and solid tumors, and is also exploring immune-mediated diseases. Key product candidates include Cemsidomide, an oral IKZF1/3 degrader in Phase 1/2 and Phase 2 clinical trials for multiple myeloma and non-Hodgkin lymphoma; CFT8919, an oral, mutant-selective EGFR L858R degrader in Phase 1 for non-small cell lung cancer; and CFT1946, a BRAF V600X degrader in Phase 1 for solid tumors. They develop both MonoDAC® (molecular glues) and BiDAC™ (heterobifunctional) degraders.

Andrew Hirsch serves as the President and CEO of C4 Therapeutics. Recent notable developments include the expansion of a long-term partnership with Roche in April 2026 to discover and develop Degrader-Antibody Conjugates (DACs). In March 2026, the first patient was dosed in the Phase 2 MOMENTUM trial for Cemsidomide. The company announced its 2025 milestones in January 2025, outlining progress across its clinical portfolio, and reported a cash runway extending into 2027 based on its financial results for the full year 2024. C4 Therapeutics also initiated a new discovery collaboration with Merck KGaA and delivered development candidates to Biogen in 2024.